Continuous Renal Replacement Therapy Market Size, Share & Trends Analysis Report By Product (System, Consumables), By Modality (Slow Continuous Ultra-Filtration, Continuous Veno-Venous Hemofiltration, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global continuous renal replacement therapy market size was valued at USD 1.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.5% from 2022 to 2030. Rising incidence of Acute Kidney Injury (AKI), increasing incidence of sepsis, rapid increase in the volume of hospitals and urgent care centers, growing hospital admissions rate, and constant product launches by prominent market players are a few factors driving the demand for CRRT, thereby propelling the market growth. In the pre-COVID-19 era, the burden of COVID-19-associated AKI climbed to almost 4 million cases per year.

As a result, the high number of COVID-19 patients who develop AKI is expected to drive the market for continuous renal replacement therapy over the forecast period. CRRT was utilized to treat roughly 23,105 AKI patients per year prior to COVID-19. The need for CRRT appears to be 5 times higher in COVID-19 patients, i.e., 4.9 percent, than in historical populations (0.9 percent). In community cohort datasets, 5%–15% of people hospitalized with COVID-19 needed dialysis. Moreover, in some North America regions, the number of people utilizing CRRT jumped by 370 percent over normal levels due to which the demand for the product has increased during the pandemic.

Furthermore, the high number of initiatives taken by the manufacturers and government during the pandemic to increase awareness regarding CRRT and CKD is expected to boost the growth of the market for continuous renal replacement therapy. For instance, Fresenius Medical Care North America's Renal Therapies Group (FMCNA) released the first batch of multiBic dialysate solutions to U.S. hospitals in May 2020, according to an FDA emergency use authorization. These medicines are intended to provide CRRT to COVID-19-related individuals with acute renal failure.

Furthermore, the pandemic of COVID-19 has also led to a surge in demand for CRRT worldwide. As a result, the market for continuous renal replacement therapy has seen an increase in financial incentives as well as regulatory support from various government agencies. These factors are expected to contribute to the CRRT market's positive growth worldwide during the forecast period. Moreover, several studies are being undertaken worldwide to assess the demand for CRRT during a pandemic. In February 2021, the journal Kidney360 released research titled "Meeting the Demand for Renal Replacement Therapy During the COVID-19 Pandemic: A Manufacturer's Perspective." The study looked at the influence of COVID-19 on the CRRT market as well as the link between AKI and COVID-19-affected patients.

AKI was diagnosed in 28 percent to 46 percent of COVID-19 hospitalized patients, according to major U.S. cohorts studied at the onset of the pandemic. Patients requiring admission/transfer to the ICU had significantly higher rates, ranging from 61 percent to 78 percent. Going forward, as lockdown restrictions are being lifted in most countries, the supply chains of most healthcare companies, including CRRT, are expected to work effectively and smoothly over the forecast period. Thus, the market for continuous renal replacement therapy is expected to grow at a significant rate in the coming years. Moreover, the COVID-19 outbreak has created opportunities for local manufacturers. These firms are adopting various plans and policies to gain a higher market share. Players are partnering with relevant third-party vendors to reinforce their foothold in the market.

The rising prevalence of fluid overload, which is common in AKI patients in critical care units, is increasing the demand for CRRT devices. In addition, the FDA has imposed tight regulations requiring manufacturers to ensure the availability of high-quality CRRT devices in intensive care units. Due to the COVID-19 pandemic, the rate of kidney infections has been increased due to which several CRRT devices such as hemofilter/hemodialyzer, delivery unit, dialysate solution, and bloodlines and tubing have been authorized by FDA for emergency use in COVID-19 patients. For instance, Prismaflex HF20 Set and Prismaflex ST Set by Baxter Healthcare Corporation and multiFiltrate PRO System and multiBic/multiPlus Solutions by Fresenius Medical are specific CRRT and hemodialysis devices authorized by FDA. Thus, COVID-19 is contributing to increasing the demand for CRRT devices during the forecast period.

The increased demand for advanced CRRT devices as a result of improved patient outcomes is a high-impact major driver of the market for continuous renal replacement therapy. The current CRRT technology has made it possible to analyze and respond to technical data in a complete manner. These improvements have resulted in a detailed examination of prescription and delivery patterns, which has had a favorable impact on clinical results from the standpoint of quality assurance. The most recent CRRT machines allow for automated data gathering and uniform language, allowing for cross-institutional comparisons. Several major market manufacturers have introduced sophisticated CRRT machines that use these technologies which are expected to boost the growth of the market.

Furthermore, the development of improved pediatric CRRT products is projected for the market for continuous renal replacement therapy in the near future. Pediatric patients who require CRRT have traditionally been treated with systems that are created and indicated for adults and are not licensed for pediatric usage, which can lead to clinical problems in neonates. As a result, various manufacturers currently offer a range of renal care solutions that enhance access to care, results, and quality of life for patients with severe renal disease or injury anywhere in the globe, regardless of their size or age, which is projected to fuel market expansion.

For instance, in December 2020, the pediatric dialysis emergency machine named Carpediem Cardio-Renal has been commercially launched in the U.S. by Medtronic plc. This technology is indicated for use in patients who require hemofiltration or hemodialysis therapy due to acute renal fluid overload or damage. It's designed to give patients who weigh between 2.5 and 10 kilos Continuous Renal Replacement Therapy (CRRT). The U.S dominated the market for continuous renal replacement therapy with the highest shares. This can be attributed to the rising prevalence of Acute Kidney Injury (AKI) and the presence of a large number of hospitals in the U.S., coupled with well-developed healthcare infrastructure.

For instance, according to American Hospital Association in 2021, there were 5,141 community hospitals, 625 nonfederal psychiatric hospitals, and 208 federal government hospitals in the U.S. In addition, a significant increase in the number of hospital admissions for AKI along with the increasing geriatric population is boosting the demand for CRRT systems, thereby propelling the market growth. Moreover, according to the Centers for Disease Control and Prevention in 2021, nearly 786,000 people in the U.S are living with ESKD, also known as end-stage renal disease (ESRD), with 71% on dialysis and 29% with a kidney transplant. Thus, with the rising prevalence of end-stage renal disease, the number of dialysis clinics and treatment centers is growing. For instance, as of 2020, there were around 7,500 dialysis clinics in the U.S. This factor is expected to positively impact market growth in the U.S.

Product Insights

The consumables segment dominated the market for continuous renal replacement therapy and held the largest revenue share of 60.6% in 2021. Hemofilters, line sets, fluid/dialysate, and accessories are among the CRRT consumables. Hemofilters, often known as artificial kidneys, are made out of a hollow-fiber membrane that decides how much solute and fluid is removed. For patients with significant renal illnesses, businesses like Baxter and Fresenius offer a variety of consumables across modalities. Although these products are inexpensive, they are frequently purchased as compared to other segments. As a result, the consumables segment is predicted to rise at an annual rate of 8.9%.

In April 2020, for example, Baxter International Inc. provided updates on its efforts to boost the global supply of critically required dialysis. As a result of an unprecedented spike in COVID-19 patients requiring Continuous Renal Replacement Therapy (CRRT), the company is witnessing demand for numerous acute dialysis products up to five times higher than historical levels. In addition, companies are continuing to work with partners and governments around the world to address these issues, as well as maximizing consumables such as fluids and setting capacity and supply to meet unprecedented surges in demand for its acute dialysis products in Europe and the U.S, which is expected to drive market growth in the near future.

Over the projection period, the system segment is expected to witness a moderate CAGR of 7.7%. The CRRT machines are mainly intended to deliver renal therapy. It consists of blood and fluid pumps, a user-friendly interface, scales, and integrated safeguards. Significant technological advancements, such as high-volume permeability of CRRT, and integration of Electronic Medical Record (EMR) connectivity, are likely to drive segment growth. Manufacturers are currently developing sophisticated devices that are safe and provide consistent performance throughout CRRT procedures. These machines also include a user-friendly interface for easy use. For instance, Baxter International Inc., in May 2021, announced the launch of PrisMax 2 worldwide, the most recent version of the company’s next-generation platform. PrisMax 2 is developed to help hospitals meet the special demands of the Intensive Care Unit (ICU) while simplifying the transfer of organ support along with continuous renal replacement therapy.

Modality Insights

The Continuous Venovenous Hemofiltration (CVVH) segment dominated the market for continuous renal replacement therapy and accounted for a revenue share of 31.5% in 2021. Over the projection period, the rising prevalence of fluid overload cases, which are commonly observed in acute kidney injury patients in critical care units, is predicted to move the CVVH segment forward. Furthermore, according to an article published by the American Society of Nephrology in 2019, congestive heart failure, which accounts for around 8% of all-cause mortality in patients with CKD stages 4 and 5, is directly linked to fluid overload, which is likely to increase the usage of CVVH treatment. Over the projection term, these variables are expected to boost segment growth.

The Continuous Venovenous Hemodiafiltration (CVVHDF) segment is expected to witness the highest CAGR of 9.1% in the market for continuous renal replacement therapy during the forecast period. CVVHDF uses a highly efficient hemodiafilter to remove both fluid and solute, combining hemodialysis and hemofiltration modalities. This treatment method results in the total removal and replacement of fluid and solute from the blood, and it is the most prevalent way of CRRT for AKI in diverse nations. Until 2008, when CVVHDF was released and became the major CRRT treatment mode, CVVH was the primary therapy modality for CRRT. The market for CVVHDF is currently predicted to increase significantly during the projection period, as it is linked to a higher survival rate than other CRRT modalities.

Regional Insights

North America dominated the continuous renal replacement therapy market and accounted for the highest revenue share of 35.6% in 2021. The key factor that is expected to contribute to market growth in this region is the increasing prevalence of the geriatric population base. With the increasing population being diagnosed with kidney disorders in the region, alternative and better methods are being followed more rigorously. Furthermore, the increasing adoption of sedentary lifestyles and unhealthy food habits is considered the highest rendering drivers for the growth of various lifestyle-related disorders such as kidney dysfunction, hypertension, and diabetes. For instance, according to the U.S. Department of Health and Human Services in 2021, about 37.0 million people, or more than 1 in 7 U.S. adult people may have Chronic Kidney Disease (CKD), which is expected to drive market growth in North America.

In the Asia Pacific, the market for continuous renal replacement therapy is expected to witness a CAGR of 9.6% during the forecast period. The high-unmet medical needs pertaining to the target disease segment, such as diabetes, hypertension, and chronic kidney disease, coupled with constantly improving healthcare expenditure in the region are some key factors attributing to market growth. In recent years, China has proven to be an attractive market for medical devices. In March 2019, the Chinese government reduced the Value Added Tax (VAT) for medical manufacturing companies from 13.3% to 13.0%.

This was likely to benefit domestic manufacturers of medical equipment, to offset the slowdown caused due to US-China trade war. Several companies, local and international, are trying to capture this opportunity by launching new and affordable products in the market. Such strategic initiatives undertaken by various companies to expand their businesses in untapped markets have led to several business transactions in the country, thereby contributing to market growth.

Key Companies & Market Share Insights

With the increased demand for CRRT products, global manufacturers are speeding up manufacturing while also improving it with cost-effective solutions. For instance, in March 2021, B. Braun Avitum AG, a manufacturer of pharmaceutical and medical devices services and products, has stated the launch of a global co-marketing contract with B. Braun's latest OMNIset Plus bloodline set (set version 3.0 or higher) and continuous purification of blood (OMNI) platform to support the use of CytoSorb.

Leading organizations in the market enforce improved product quality through mergers and acquisitions and increase awareness regarding the diseases to support education for healthcare professionals. For instance, in June 2021, Fresenius Medical Care inaugurated its training center in Korea, to support education for healthcare professionals in critical care, renal care, and treatment strategies. These training programs will help enhance knowledge within the industry, increasing the potential for improved patient care which is anticipated to spur market growth in the near future. Some of the prominent players in the continuous renal replacement therapy market include:

• B. Braun Melsungen AG

• Baxter International, Inc.

• Fresenius Medical Care AG & Co. KGaA

• Asahi Kasei Corporation

• NIPRO Corporation

• Toray Medical Co., Ltd

• NxStage Medical, Inc.

• Medtronic plc & Others

Continuous Renal Replacement Therapy Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2017 to 2030. Grand View Research has segmented the global continuous renal replacement therapy market report based on product, modality, and region:

• Product Outlook (Revenue, USD Million, 2017 - 2030)

  • System

  • Consumables

• Modality Outlook (Revenue, USD Million, 2017 - 2030)

  • Slow Continuous Ultra-Filtration (SCUF)

  • Continuous Veno-venous Hemofiltration (CVVH)

  • Continuous Veno-venous Hemodialysis (CVVHD)

  • Continuous Veno-venous Hemodiafiltration (CVVHDF)

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE